Sepsis is a brutal killer. It often starts after a microorganism gets loose in your bloodstream, spreading to organs far and wide, releasing deadly toxins along the way. In response, your body releases toxins of its own, chemicals designed to kill the invading organism but that, all too often, damage your body, too, leaving you…
Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet. Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at…
Purdue Pharma launched OxyContin in 1996, and soon began an aggressive marketing campaign for this powerful and addictive drug. The campaign is over, but its effects are still deadly. How do we know this? Because Purdue’s marketing wasn’t sprinkled evenly around the country. Instead, Purdue rolled out its campaign in different markets at different times…
The patient arrived in my clinic, their right big toe the color of a spring strawberry. The lightest touch caused exquisite pain. Fortunately, I was able to prescribe a pill (an ancient medicine, actually) and the patient was better by the next day.
Too bad that simple treatment is becoming unaffordable, through a maddening combination of greed and regulatory failure.
Covid-19 killed approximately 60,000 young Americans between 15 and 54 years old in 2021. By any measure, that is an awful statistic, representing a staggering number of loved ones lost to the virus.
But as awful as that statistic is, guess what killed even more young Americans.
A whole industry is devoted to measuring, tracking and even incentivizing the quality of American hospital care. Unfortunately, that industry is horribly inefficient, costing us billions of dollars.
Quality measurement is inefficient in large part because there is no single source that hospitals (and provider systems, more generally) can use to track the quality of their care.
The Medicare Diabetes Prevention Program is a lifesaver. Consisting of of at least 16 class sessions that provide practical training about healthy eating, physical activity, and other strategies for weight control, the Program reduces the chance that people at high risk for diabetes actually develop that life-threatening condition.
However, the Program is floundering, with distressingly few people having access to or enrolling in the program. Could it be because Medicare administrators haven’t watched enough episodes of Shark Tank?
Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the U.S. In Canada, the price is closer to $500.
Ibrance, a breast cancer drug, costs $10,000 more per month in the U.S. than in Canada.
Why these enormous price differences?
Many people die in ways, and even in locations, that go against their preferences. They don’t want to be put on ventilators and, yet, spend their last days in intensive care units tethered to breathing machines. They don’t want cardiopulmonary resuscitation (CPR), and, yet, receive full-on “codes” when their hearts stop.
Much of this unwanted care could be avoided if patients (aka: “people”) discussed their treatment preferences with their clinicians.
How is a physician supposed to know which medicine is most affordable under which insurance plan?
Fortunately, there are tools coming into use designed to help clinicians figure out patient-specific costs of any medication they prescribe. The tools (jargon alert!) are called RTBTs, for real-time benefit tools.